Want to see FR:ALPAT full AI Analyst Report?
Plant Advanced Technologies SA (ALPAT) AI Stock Analysis
Plant Advanced Technologies SA
(Paris:ALPAT)
The score is primarily supported by improved 2024 financial performance (profitability, cash generation, and lower leverage). It is held back by mixed technicals (below the 200-day average and slightly negative MACD) and weak/unclear valuation signals due to a negative P/E and no dividend yield.
Plant Advanced Technologies SA (ALPAT) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 4.06M
- Dividend Yield
- ―
- Average Volume (3M)
- 313
- Price to Earnings (P/E)
- 7.0
- Beta (1Y)
- 0.18
- Revenue Growth
- -40.95%
- EPS Growth
- -39.70%
- Country
- France
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Plant Advanced Technologies SA Business Overview & Revenue Model
Company Description
Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include Process PAT Exudactive a sustainable sourcing solution to produce you...
How the Company Makes Money
null
Plant Advanced Technologies SA Financial Statement Overview
Summary
2024 shows a meaningful turnaround with strong profitability, improved leverage, and solid operating/free cash flow. The score is capped by the small revenue base and historically volatile results, including sustained losses and weak/negative cash flow in 2020–2022.
Income Statement
66PositiveBalance Sheet
64PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.14M | 1.14M | 1.93M | 1.68M | 2.34M | 2.31M |
| Gross Profit | -693.73K | -693.73K | 2.24M | 2.15M | -4.65M | -2.73M |
| EBITDA | 205.66K | -693.73K | 956.45K | 185.78K | -744.00K | -1.27M |
| Net Income | 569.40K | 569.40K | 935.13K | 79.17K | -849.00K | -1.13M |
Balance Sheet | ||||||
| Total Assets | 16.37M | 16.37M | 16.00M | 14.91M | 17.08M | 17.11M |
| Cash, Cash Equivalents and Short-Term Investments | 55.00K | 55.00K | 79.70K | 0 | 669.00K | 2.49M |
| Total Debt | 3.74M | 3.62M | 3.42M | 4.36M | 5.97M | 6.14M |
| Total Liabilities | 6.53M | 6.53M | 6.83M | 6.78M | 10.29M | 9.73M |
| Stockholders Equity | 9.84M | 9.84M | 9.17M | 8.13M | 5.50M | 6.36M |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | 2.08M | 972.53K | -479 | -504 |
| Operating Cash Flow | 0 | 0 | 2.50M | 1.85M | -274 | -388 |
| Investing Cash Flow | 0 | 0 | -1.59M | -1.28M | -1,968 | -1,111 |
| Financing Cash Flow | 0 | 0 | -585.89K | -851.03K | 244 | 743 |
Plant Advanced Technologies SA Peers Comparison
Overall Rating
FR:ALPAT60Neutral
FR:ALTME48Neutral
FR:POXEL46Neutral
FR:ALNEV43Neutral
FR:ALBPS42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | EUR 4.04M | 6.98 | ― | ― | -40.95% | -39.70% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | EUR 11.77M | -3.55 | 305.72% | ― | ― | ― | |
| 46Neutral | EUR 8.87M | -0.43 | 33.88% | ― | ― | ― | |
| 43Neutral | EUR 173.61K | 0.00 | -26.52% | ― | -44.46% | 100.00% | |
| 42Neutral | EUR 11.52M | -0.01 | 153.48% | ― | ― | 90.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALPAT | Plant Advanced Technologies SA | 3.56 | -4.94 | -58.12% | |
| FR:POXEL | Poxel SA | 0.17 | -0.17 | -50.30% | |
| FR:ALTME | TME Pharma N.V. | 0.12 | 0.03 | 36.26% | |
| FR:ALBPS | Biophytis SA | 0.03 | -0.08 | -71.70% | |
| FR:ALNEV | Neovacs SA | 0.10 | -375.90 | -99.97% |
Plant Advanced Technologies SA Corporate Events
Plant Advanced Technologies Enters Court-Supervised Restructuring to Support Recovery Plan
Plant Advanced Technologies SA has been placed under court-supervised restructuring by the Commercial Court of Nancy after declaring a suspension of payments, with a renewable six-month observation period that freezes its liabilities and secures a le...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Feb 03, 2026